Phio Pharmaceuticals: Undervalued Innovator with Promising siRNA Therapy and Strategic Growth Potential

Matthew Keller, an analyst from H.C. Wainwright, has initiated a new Buy rating on Phio Pharmaceuticals (PHIO).

Matthew Keller’s rating is based on several compelling factors. Phio Pharmaceuticals’ lead asset, PH-762, is a next-generation siRNA therapy designed to inhibit PD-1 expression on T cells, which is crucial for driving anti-tumor activity. This innovative approach, developed using Phio’s proprietary INTASYL platform, aims to enhance drug delivery and efficacy while minimizing adverse side effects. The potential of PH-762 to become the first siRNA therapy approved for solid tumors, including cutaneous carcinomas, adds to the optimism surrounding the stock.
Furthermore, Phio Pharmaceuticals is seen as undervalued in the market, with PH-762 already showing promising clinical activity and safety in a Phase 1b trial. Despite the crowded skin cancer therapy market, there remains a high unmet need due to the high incidence of tumors and suboptimal efficacy of existing treatments. Additionally, Phio’s preclinical portfolio holds significant long-term potential, and the company’s openness to business development and partnering opportunities is viewed as a strategic advantage. These elements contribute to the belief that Phio Pharmaceuticals has substantial upside potential, justifying the Buy rating.

According to TipRanks, Keller is an analyst with an average return of -20.0% and a 22.22% success rate. Keller covers the Healthcare sector, focusing on stocks such as FibroGen, Iterum Therapeutics, and Phio Pharmaceuticals.